Plexus Ventures LLC

Belkins
Plexus Ventures is a leading global business development firm serving the pharmaceutical industry for 26 years. We provide business development services to clients in the pharmaceutical, biotechnology, consumer health, and drug delivery industries worldwide.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

RESEARCH

ASCENTAGE PHARMA ENTERS INTO AN AGREEMENT WITH UNIVERSITY OF MICHIGAN TO OBTAIN AN EXCLUSIVE LICENSE FOR DEGRADER

Ascentage Pharma | November 30, 2020

news image

Ascentage Pharma (6855.HK), an internationally engaged, clinical-stage biotechnology organization occupied with creating novel treatments for malignant growths, ongoing hepatitis B (CHB), and age-related infections, today reported it has gone into a concurrence with the University of Michigan, through which the organization may acquire the selective worldwide rights to a MDM2 protein degrader created utilizing the Proteolysis-Targeting Chimeras (PROTACs) innovation. The medication competitor is ...

Read More

FIRST GENE THERAPY CLINICAL TRIAL TO ADDRESS GENETIC BLINDNESS

PharmaNewsIntelligence | March 11, 2020

news image

Oregon Health & Science University (OHSU) held the first-ever gene therapy clinical trial, BRILLIANCE, to address blindness-causing gene mutation, LCA10, according to a recent press release The clinical trial, sponsored by Allergan plc and Editas Medicine, is one of 14 different clinical trials investigating new genetic treatments for ophthalmic conditions and nearly 50 vision-related clinical trials. The procedure uses gene-editing tool CRISPR to edit human genes, also known as in vivo gene...

Read More

TETRA BIO-PHARMA GETS ORPHAN DRUG STATUS FOR CBD DRUG

Greenmarketreport | April 22, 2020

news image

Tetra Bio-Pharma Inc. (OTCQB:TBPMF) announced its Orphan Drug development strategy and provided a management update. The company said it is focusing on generating intellectual property including use, manufacturing, and innovative molecule protection. Tetra said it received a U.S. Food and Drug Administration (FDA) Orphan Drug Designation for secondary cannabidiol (CBD) formulation of its cannabinoid topical drug PPP004 in the treatment of epidermolysis bullosa. “Each ODD application is dri...

Read More

REASONS FOR HOPE: THE DRUGS, TESTS AND TACTICS THAT MAY CONQUER CORONAVIRUS

Times Now | April 14, 2020

news image

With much of the world living in lockdown, the spread of the new coronavirus, SARS-CoV-2, that was first detected in China late last year is beginning to slow in some places. As of April 12, 1.8 million had been infected and 115,000 killed by COVID-19, the disease caused by the virus. While a safe, effective vaccine is still more than a year away, researchers are rushing to repurpose existing drugs and non-drug therapies as well as testing promising experimental drugs that were already in clinic...

Read More

RESEARCH

Ascentage Pharma | November 30, 2020

news image

ASCENTAGE PHARMA ENTERS INTO AN AGREEMENT WITH UNIVERSITY OF MICHIGAN TO OBTAIN AN EXCLUSIVE LICENSE FOR DEGRADER

Ascentage Pharma (6855.HK), an internationally engaged, clinical-stage biotechnology organization occupied with creating novel treatments for malignant growths, ongoing hepatitis B (CHB), and age-related infections, today reported it has gone into a concurrence with the University of Michigan, through which the organization may acquire the selective worldwide rights to a MDM2 protein degrader created utilizing the Proteolysis-Targeting Chimeras (PROTACs) innovation. The medication competitor is ...

Read More

PharmaNewsIntelligence | March 11, 2020

news image

FIRST GENE THERAPY CLINICAL TRIAL TO ADDRESS GENETIC BLINDNESS

Oregon Health & Science University (OHSU) held the first-ever gene therapy clinical trial, BRILLIANCE, to address blindness-causing gene mutation, LCA10, according to a recent press release The clinical trial, sponsored by Allergan plc and Editas Medicine, is one of 14 different clinical trials investigating new genetic treatments for ophthalmic conditions and nearly 50 vision-related clinical trials. The procedure uses gene-editing tool CRISPR to edit human genes, also known as in vivo gene...

Read More

Greenmarketreport | April 22, 2020

news image

TETRA BIO-PHARMA GETS ORPHAN DRUG STATUS FOR CBD DRUG

Tetra Bio-Pharma Inc. (OTCQB:TBPMF) announced its Orphan Drug development strategy and provided a management update. The company said it is focusing on generating intellectual property including use, manufacturing, and innovative molecule protection. Tetra said it received a U.S. Food and Drug Administration (FDA) Orphan Drug Designation for secondary cannabidiol (CBD) formulation of its cannabinoid topical drug PPP004 in the treatment of epidermolysis bullosa. “Each ODD application is dri...

Read More

Times Now | April 14, 2020

news image

REASONS FOR HOPE: THE DRUGS, TESTS AND TACTICS THAT MAY CONQUER CORONAVIRUS

With much of the world living in lockdown, the spread of the new coronavirus, SARS-CoV-2, that was first detected in China late last year is beginning to slow in some places. As of April 12, 1.8 million had been infected and 115,000 killed by COVID-19, the disease caused by the virus. While a safe, effective vaccine is still more than a year away, researchers are rushing to repurpose existing drugs and non-drug therapies as well as testing promising experimental drugs that were already in clinic...

Read More